TCGA-62-A46S-01A-11R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.280
- KRAS_SIGNALING_UP+0.260
- BILE_ACID_METABOLISM+0.230
- ANDROGEN_RESPONSE+0.200
- COAGULATION+0.200
- KRAS_SIGNALING_DN+0.160
- FATTY_ACID_METABOLISM+0.130
- ANGIOGENESIS+0.120
- IL2_STAT5_SIGNALING+0.100
- TNFA_SIGNALING_VIA_NFKB+0.100
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.530
- MITOTIC_SPINDLE-0.410
- MTORC1_SIGNALING-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- DNA_REPAIR-0.350
- PI3K_AKT_MTOR_SIGNALING-0.330
- APICAL_SURFACE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A55O-01A-11R-A262-07 | — | cohortA2 | 0.863 |
| 2 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.862 |
| 3 | C3L-03642 | — | cohortA1 | 0.858 |
| 4 | TCGA-K4-A3WU-01B-11R-A23N-07 | — | — | 0.845 |
| 5 | C3L-03679 | — | cohortA1 | 0.838 |
| 6 | TCGA-67-4679-01B-01R-1755-07 | — | cohortA1 | 0.837 |
| 7 | TCGA-91-8497-01A-11R-2403-07 | — | cohortA1 | 0.826 |
| 8 | C3N-03911 | — | cohortA1 | 0.822 |
| 9 | C3N-03038 | — | cohortA1 | 0.820 |
| 10 | MDT-AP-3030 | Med | Medulloblastoma | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |